Sodium Chloride 0.9% in Plastic Container

125 mL Syringe: Sodium Chloride Injection USP 0.9% is indicated for use in flushing compatible contrast agents through Liebel-Flarsheim intravenous administration sets into indwelling intravascular access devices only when delivered by the following Liebel-Flarsheim power injectors: Angiomat ® , Illumena ® , Illumena ® Néo, CT9000 ® , CT9000 ® ADV, Optistat ® , Optivantage ® and Optistar Elite. For use in flushing compatible contrast agents through Liebel-Flarsheim intravenous administration sets into indwelling intravascular access devices ( 1 )

None None ( 4 )

Remove all air from the syringe and associated tubing prior to injection. ( 5.1 ) May cause fluid overload in patients with congestive heart failure, severe renal insufficiency, and in clinical states with edema, sodium retention, or hypernatremia. ( 5.3 ) Establish intravascular catheter patency prior to administration. ( 5.4 )

5.1Air Embolism

Remove all air from the syringe and associated tubing prior to injection to avoid air embolus with the associated risk of stroke, organ ischemia and/or infarction, and death.

5.2 Infectious Complications Use of a damaged syringe or failure to maintain aseptic technique may result in infection, sepsis and death [ see Dosage and Administration (2) ].

5.3Fluid Overload Sodium Chloride Injection USP

0.9% may cause fluid overload in patients with congestive heart failure, severe renal insufficiency, and in clinical states with edema, sodium retention, or hypernatremia. Consider each patient’s age, body weight, fluid status, concomitant medical conditions and planned radiological procedure to determine if use of Sodium Chloride Injection USP 0.9% is appropriate.